Sensyne Health PLC NED Appointment (3143C)

TIDMSENS

RNS Number : 3143C

Sensyne Health PLC

18 June 2021

Board Appointment

Dr Ian Hudson to join as Independent Non-Executive Director

Oxford, U.K. 18 June 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announces the appointment of Dr Ian Hudson to the Board as Independent Non-Executive Director with effect from 28 June 2021.

Dr Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as Chief Executive of the UK's Medicines and Healthcare Products Regulatory Agency ("MHRA") between 2013 and 2019. Prior to this, he was the MHRA's Licensing Director, responsible for most of the agency's medicines licensing activities.

Before joining the MHRA, Dr Hudson held various senior roles at SmithKline Beecham, working for more than a decade in clinical research and development. Dr Hudson is currently serving as Senior Advisor, Integrated Development for the Bill and Melinda Gates Foundation, working in areas that include optimizing clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and COVID-19 drugs.

In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President's medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine.

Professor Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said : " I am thrilled to welcome Ian to the Board at such an important time for Sensyne. Ian's experience will be a great asset as we build an innovative and world class clinical artificial intelligence company."

Dr Ian Hudson, Independent Non-Executive Director of Sensyne, said: "The COVID-19 pandemic has demonstrated how important clinical AI is to the effective management of health. Sensyne has been at the forefront of this trend, applying ethical AI to improving healthcare and life sciences research and I'm looking forward to supporting the company on what is an increasingly global journey."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr Ian Robert Burton Hudson (age 62)

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Dr Hudson.

-ENDS-

For more information please contact:

 
  Sensyne Health ( www.sensynehealth.com )                   [phone] 
  Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive 
   Officer 
  Richard Pye, Chief Financial Officer 
 
    Peel Hunt LLP (Nominated Adviser and Joint Broker)         + 44 (0) 20 7418900 
  Dr Christopher Golden 
  James Steel 
  Oliver Jackson 
  Liberum (Joint Broker)                                     + 44 (0) 201002000 
  Bidhi Bhoma 
  Euan Brown 
  Consilium Strategic Communications                         [phone] 
  Mary-Jane Elliott 
  Jessica Hodgson 
  Davide Salvi 
  [e-mail] 
 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAKDLFFFQLXBBX

(END) Dow Jones Newswires

June 18, 2021 02:00 ET (06:00 GMT)